More than three out of four patients with relapsed multiple myeloma, or myeloma that was refractory to at least two therapies, remained in remission 7 months after treatment with a novel chimeric antigen receptor (CAR) T-cell therapy targeting two proteins that are frequently found on myeloma cells. Those experiencing sustained remissions included patients with extramedullary disease. These findings were reported by Li et al at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 930).
Roughly 1 in 10 patients with multiple myeloma develop tumors in the organs or soft tissues such as the blood vessels, muscles, and nerves. These extramedullary tumors respond poorly to treatment, and patients who develop them have a poor outlook and poor quality of life, said study author Yu Hu, MD, PhD, of Union Hospital, Huazhong University of Science and Technology in Wuhan, China.
“Our results show that this CAR T-cell product can effectively achieve elimination of extramedullary tumors,” said Dr. Hu. “Although these are preliminary data, they are encouraging for patients with multiple myeloma who have not responded to other therapies.”
The study treatment is the first CAR T-cell therapy to be genetically engineered to target B-cell maturation antigen (BCMA) and CD38, two proteins found on the surface of plasma cells. “Our thinking was that targeting both of these proteins would improve treatment efficacy without increasing toxicity, and induce deeper, more durable remissions,” said Dr. Hu.
“Our results show that this CAR T-cell product can effectively achieve elimination of extramedullary tumors. Although these are preliminary data, they are encouraging for patients with multiple myeloma who have not responded to other therapies.”— Yu Hu, MD, PhD
Tweet this quote
The first-in-humans phase I trial enrolled 22 patients (average age = 59), of whom 11 were men. All had multiple myeloma that had returned or not responded to at least three therapies. Nine of the 22 patients had extramedullary tumors. The study aims were to determine the safest and most effective dose of the CAR T-cell therapy as well as to initially evaluate its effectiveness.
Patients received 3 days of chemotherapy, then each patient was infused with the dual-targeted CAR T cells. Patients were divided into five groups, with each group receiving a higher dose than the previous one. Depending on the cell dose, patients received either one or two infusions.
At a median of 36 weeks of follow-up, 18 patients (90.9%) had minimal residual disease–negative multiple myeloma. Twelve patients (54.5%) had a stringent complete response. Seven patients (31.8%) had a good or very good partial response. In eight of the nine patients with extramedullary lesions, tumors were undetectable on their computed tomography scans. For the 17 patients who remained in remission at 7 months after treatment, the median duration of response was 28.8 weeks.
Researchers observed some side effects. Twenty patients experienced cytokine release syndrome, and 6 of the 20 needed treatment for its symptoms. No serious adverse neurologic effects such as seizures, movement impairment, difficulty speaking or understanding speech, or fatal swelling in the brain were reported.
“With this dual-targeted CAR T-cell therapy, we have demonstrated a high response rate—especially a higher rate and longer duration of stringent complete response—compared with other therapies, as well as effective elimination of extramedullary lesions, with no serious neurologic adverse effects and manageable levels of other adverse effects,” said Dr. Hu.
The investigators will continue to follow the patients for 2 years. They are also planning to conduct a phase II trial in both China and the United States to test the treatment’s effectiveness in a larger number of patients.
Disclosures: This study was supported by the National Natural Science Foundation of China, the Major Technological Innovation Special Project fund of Hubei Province of China, and Cellyan Therapeutics Co., Ltd. For full disclosures of the study authors, visit ash.confex.com.The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.